LWM
TERN

LeConte Wealth Management’s Terns Pharmaceuticals TERN Stock Holding History

LeConte Wealth Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,641
Closed -$47.2K – 140
2025
Q2 		$47.2K Buy
+12,641
New +$39.5K 0.03% 104

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

LeConte Wealth Management's TERN Position: Q3 2025 in Review

LeConte Wealth Management sold out of Terns Pharmaceuticals (TERN) in Q3 2025, closing a stake of 12,641 shares — an estimated $47.2K sold.

LeConte Wealth Management first reported a position in TERN in Q2 2025 and held it in 1 quarter. The position peaked at $47.2K in Q2 2025. 141 funds tracked by Wall St. Rank hold TERN as of Q3 2025.

  • LeConte Wealth Management reported no remaining Terns Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • LeConte Wealth Management sold 12,641 Terns Pharmaceuticals shares in Q3 2025, an estimated $47.2K.
  • LeConte Wealth Management first reported a position in Terns Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • LeConte Wealth Management's Terns Pharmaceuticals position peaked at $47.2K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2025.

Based on LeConte Wealth Management's 13F filing for Q3 2025, filed 16 Oct 2025.